Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

182.30EUR
24 May 2017
Change (% chg)

-- (--)
Prev Close
€182.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,995
52-wk High
€191.10
52-wk Low
€109.00

BIOX.PA

Chart for BIOX.PA

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.38
Market Cap(Mil.): €7,180.58
Shares Outstanding(Mil.): 39.45
Dividend: 1.00
Yield (%): 0.55

Financials

  BIOX.PA Industry Sector
P/E (TTM): 39.98 31.20 17.36
EPS (TTM): 4.55 -- --
ROI: 8.26 12.79 -5.72
ROE: 11.50 15.28 -5.10

BRIEF-Chairman Mustafa Latif Topbas transfers 14.78 pct stake in BIM to Merkez Bereket Gida-KAP

* CHAIRMAN MUSTAFA LATIF TOPBAS TRANSFERS HIS 14.78 PCT DIRECT STAKE IN BIM TO MERKEZ BEREKET GIDA AT 61.0 LIRA PER SHARE-KAP

May 16 2017

BRIEF-Biomerieux Q1 Consolidated sales rise to 568 million euros

* Consolidated sales rose to 568 million euros ($609.18 million) for the first three months of 2017, up from 489 million euros in the same period one year earlier Source text: http://bit.ly/2piknxJ Further company coverage: ($1 = 0.9324 euros) (Gdynia Newsroom:)

Apr 20 2017

BRIEF-Biomerieux receives FDA 510(k) clearance for BacT/ALERT VIRTUO fully automated blood culture system

* Biomerieux receives FDA 510(k) clearance for its BacT/ALERT VIRTUO fully automated blood culture system Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 06 2017

Turkey's BIM 2016 net profit rises 15 percent

ISTANBUL, March 7 Turkish retailer BIM posted a net profit of 670.9 million lira ($181 million) in 2016, up 15 percent from a earlier, it said in a statement to the Istanbul stock exchange late on Monday.

Mar 06 2017

BRIEF-Biomerieux FY sales up 7.1 pct as reported at 2.10 billion euros

* Board of directors will recommend that shareholders at annual meeting on May 30 approve a dividend of 1.00 euros per share

Mar 01 2017

BRIEF-Biomerieux launches first FDA-cleared procalcitonin assay

* Biomérieux’s VIDAS BRAHMS PCT becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 24 2017

BRIEF-Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury

* Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury

Jan 19 2017

BRIEF-Biomerieux 2016 sales up at 2,103 million euros

* Remarkable growth in sales in 2016, up 9.6 pct like-for-like, lifted by all regions and all strategic lines

Jan 19 2017

More From Around the Web

Earnings vs. Estimates